



**CONSOLIDATED INTERIM REPORT FOR THE
FIRST 6 MONTHS OF 2024
(UNAUDITED)**

beginning of financial year: 01.01.2024

end of the financial year: 30.06.2024

business name: J.Molner AS

register code: 16579077

postal address: Harju maakond, Tallinn, Mustamäe linnaosa,
Akadeemia tee 21/5

postal code: 12618

e-mail address: jmolner@jmolner.com

Table of contents

Management report	3
The Consolidated interim accounts	5
Consolidated statement of financial position	5
Consolidated income statement	6
Consolidated statement of cash flows	7
Consolidated statement of changes in equity	8
Notes	9
Note 1 Accounting policies	9
Note 2 Cash and cash equivalents	12
Note 3 Receivables and prepayments	12
Note 4 Inventories	13
Note 5 Shares of subsidiaries	13
Note 6 Property, plant and equipment	14
Note 7 Intangible assets	15
Note 8 Loan commitments	16
Note 9 Payables and prepayments	17
Note 10 Employee payables	17
Note 11 Net sales	18
Note 12 Miscellaneous operating expenses	18
Note 13 Labor expense	19
Note 14 Related parties	19
Note 15 non-consolidated statement of financial position	20
Note 16 non-consolidated income statement	21
Note 17 non-consolidated statement of cash flows	21
Note 18 non-consolidated statement of changes in equity	22
Signatures	23

Management report

The Management Report has been prepared for the consolidated financial results of J. Molner AS, The J. Molner Company OÜ and The J. Molner Company LLC (hereinafter the "Group") for the first half year of 2024.

During the first half of year 2024, the Group continued the development of its own generic drugs and the provision of analytical chemistry and method development services to third parties. Revenue for the first six months 2024 increased to EUR 1,305,327, up 382% from the same period 2023. Growth was achieved through the performance of our hydrocortisone butyrate topical solution in the United States and a growth in our analytical and development services in the United States, Canada, and Europe.

The Group continued to invest in its pipeline of pharmaceuticals for the United States and Canada. In April 2024, we received approval for the first Estonian-developed abbreviated new drug application ("ANDA") from the US Food and Drug Administration ("FDA"). We anticipate launching this product in the fourth quarter of 2024. In addition, we continued our development efforts to return to market two further approved ANDAs owned by the Group and five licensed products for the US market. We anticipate reintroducing two of these products in the second half of 2024 and the balance in 2025, subject to satisfactory data and the consent of the US FDA.

In Canada, the Group's marketing partner launched the first of our injectable drugs, norepinephrine bitartrate, to market in June 2024. We have one further pending abbreviated new drugs submission ("ANDS") under active review at Health Canada. We continue to evaluate opportunities to build our pipeline of drugs for the institutional sector in Canada through a combination of inlicensing, development, and acquisition.

Important notes:

- The Group's business is not seasonal.
- The Group's activities are not accompanied by significant environmental and social impacts.
- Interest rates did not change significantly during the financial year and the period of preparation of the annual report.

As per 30.06.2024 the total consolidated unaudited balance sheet of J. Molner AS was EUR 4,306,345 (as per 30.06.2023, EUR 2,338,793). The total consolidated balance sheet increased by 84% compared to the total consolidated balance sheet on 30.06.2023. As per 30.06.2024, consolidated current assets amounted to EUR 1,217,724 (as per 30.06.2023 EUR 933,392), which is 28% of total assets (as per 30.06.2023 40%).

As per 30.06.2024 consolidated fixed assets amounted to EUR 3,088,621 (as per 30.06.2023 EUR 1,405,401), which is 72% of total assets (as per 30.06.2023 60%). As per 30.06.2024 the consolidated liabilities of J. Molner AS amounted to EUR 3,460,225 (as per 30.06.2023 EUR 1,429,663), which is 80% of the total balance sheet (as per 30.06.2023 61%). As per 30.06.2024 the consolidated equity was EUR 846,120 (as per 30.06.2023 EUR 909,130), which is 20% from total balance sheet (as per 30.06.2023 39%).

In the first half of 2024 the Group's investments to fixed assets were EUR 481,683, including EUR 358,589 on research and development. Depreciation expenses for the first 6 months of 2024 amounted to EUR 42,628.

In January 2024, subsidiary of J. Molner AS The J. Molner Company OÜ concluded a subordinated loan agreement with no specific repayment term which extended the existing credit facility of The J. Molner Company OÜ up to USD 2,750,000. The interest rate applicable in respect of the additional amount is 7% per year. As per 30.06.2024 the consolidated unaudited loan liabilities were EUR 2,686,917 (as per 30.06.2023 EUR 1,206,153), of which EUR 279,734 is short term liabilities (as per 30.06.2023 EUR 277,483) and EUR 2,407,183 (as per 30.06.2023 EUR 928,670) is long term liabilities. In the first half of 2024 interest on the loans was EUR 137,120. In the period 01.01.2023-30.06.2023 the interest on loans was EUR 56,969 EUR.

As per 30.06.2024 the consolidated unaudited sales revenue was EUR 1,305,327, on 30.06.2023 the consolidated unaudited sales revenue was EUR 270,769. Consolidated unaudited sales revenue for the first half of 2024 increased by 382% compared to the first half of 2023. In 30.06.2024 the consolidated unaudited loss was EUR 982,119, on 30.06.2023 the consolidated unaudited loss was EUR 444,526.

As per 30.06.2024 The Group had 29 employees, 1 member of the management board and 3 members of the supervisory board. In January – June 2024 the consolidated unaudited labor costs amounted to EUR 721,973, of which EUR 5,125 was the costs of the reserve provided to employees.

Financial Ratios	30.06.2024	30.06.2023
Current Ratio	1,16	1,86
Net Working Capital	164 682	432 399
EBITDA	-724 972	-378 369
Equity Ratio, %	19,65	38,87
Return on Total Assets, %	-75,24	-164,17
Total Debt Ratio, x	0,80	0,61

Current Ratio = Current assets / Current liabilities

Net Working Capital = Current assets - Current liabilities

EBITDA = Operating profit + Depreciation and impairment loss

Equity Ratio = Equity / Cost of Assets *100

Return on Total Assets = Net Profit / Revenue *100

Total Debt Ratio = Liabilities / Total liabilities and owners' equity

The consolidated interim accounts

Consolidated statement of financial position

(In Euros)

	30.06.2024	31.12.2023	30.06.2023	Note
Assets				
Current assets				
Cash and cash equivalents	611 512	92 522	675 300	2
Receivables and prepayments	518 601	316 330	248 704	3
Inventories	87 611	72 242	9 388	4
Total current assets	1 217 724	481 094	933 392	
Non-current assets				
Investments in subsidiaries and associates	262	263	263	
Receivables and prepayments	9 595	9 595	2 377	3
Property, plant and equipment	291 511	213 402	159 185	6
Intangible assets	2 787 253	2 426 307	1 243 576	7
Total non-current assets	3 088 621	2 649 567	1 405 401	
Total assets	4 306 345	3 130 661	2 338 793	
Liabilities and equity				
Liabilities				
Current liabilities				
Loan liabilities	279 734	267 645	277 483	8
Payables and prepayments	773 308	688 677	223 510	9,10
Total current liabilities	1 053 042	956 322	500 993	
Non-current liabilities				
Loan liabilities	2 407 183	1 911 170	928 670	8
Total non-current liabilities	2 407 183	1 911 170	928 670	
Total liabilities	3 460 225	2 867 492	1 429 663	
Equity				
Equity held by shareholders and partners in parent company				
Issued capital	1 686 001	1 686 001	1 686 001	
Share premium	612 327	612 327	612 327	
Other reserves	3 401 781	1 836 711	1 842 013	
Retained earnings (loss)	-3 871 870	-2 786 685	-2 786 685	
Annual period profit (loss)	-982 119	-1 085 185	-444 526	
Total equity held by shareholders and partners in parent company	846 120	263 169	909 130	
Total equity	846 120	263 169	909 130	
Total liabilities and equity	4 306 345	3 130 661	2 338 793	

Consolidated income statement

(In Euros)

	01.01.2024 - 30.06.2024	01.01.2023 - 30.06.2023	Note
Revenue	1 305 327	270 769	11
Other income	7 198	4 636	
Work performed by entity and capitalised	275 301	282 793	
Raw materials and consumables used	-1 043 961	-93 127	
Other operating expense	-538 222	-320 150	12
Employee expense	-721 973	-517 658	13
Depreciation and impairment loss (reversal)	-42 628	-9 458	6,7
Other expense	-8 642	-5 632	
Operating profit (loss)	-767 600	-387 827	
Interest expenses	-137 120	-56 969	
Other financial income and expense	-77 399	270	
Profit (loss) before tax	-982 119	-444 526	
Annual period profit (loss)	-982 119	-444 526	
Profit (loss) from shareholders and partners in parent company	-982 119	-444 526	

Consolidated statement of cash flows

(In Euros)

	01.01.2024 - 30.06.2024	01.01.2023 - 30.06.2023
Cash flows from operating activities		
Receipts of sales of goods and rendering of services	843 854	205 681
Payments to suppliers for goods and services	-1 205 401	-714 684
Payments to employees	-410 201	-264 531
Other cash flows from operating activities	-247 943	-87 090
Total cash flows from operating activities	-1 019 691	-860 624
Cash flows from investing activities		
Purchase of property, plant and equipment and intangible assets	-511 638	-93 452
Other cash payments to acquire other financial investments	0	-2 377
Interest received	51	63
Total cash flows from investing activities	-511 587	-95 766
Cash flows from financing activities		
Loans received	1 847 705	908 894
Other cash inflows from financing activities	202 563	0
Total cash flows from financing activities	2 050 268	908 894
Total cash flows	518 990	-47 496
Cash and cash equivalents at beginning of period	92 522	722 796
Change in cash and cash equivalents	518 990	-47 496
Cash and cash equivalents at end of period	611 512	675 300

Consolidated statement of changes in equity

(In Euros)

	Equity held by shareholders and partners in parent company				Total
	Issued capital	Share premium	Other reserves	Retained earnings (loss)	
	31.12.2022	1 686 001	612 327	750 000	
Annual period profit (loss)	0	0	0	-444 526	-444 526
Changes in reserves	0	0	1 092 013	0	1 092 013
30.06.2023	1 686 001	612 327	1 842 013	-3 231 211	909 130
Annual period profit (loss)	0	0	0	-640 659	-640 659
Changes in reserves	0	0	-5 302	0	-5 302
31.12.2023	1 686 001	612 327	1 836 711	-3 871 870	263 169
Annual period profit (loss)	0	0	0	-982 119	-982 119
Changes in reserves	0	0	1 565 070	0	1 565 070
30.06.2024	1 686 001	612 327	3 401 781	-4 853 989	846 120

* In the first half of 2024, the voluntary reserve increased in the amount of EUR 1,559,945 as of 30.06.2024 and the option reserve of 5,125 euros are reflected in changes in other reserves.

Notes

Note 1 Accounting policies

General information

The financial accounts of J. Molner AS for the first half of financial year 2024 have been prepared in accordance with the Estonian financial reporting standard. The Estonian financial reporting standard is established by the Accounting Act of the Republic of Estonia, which is supplemented by the guidelines issued by the Accounting Standards Board.

This is a consolidated unaudited interim report of a medium sized business.

The interim accounts have been prepared in Euros.

The principal accounting policies adopted are set out below.

Preparation of consolidated statements

In the consolidated report, all subsidiaries are consolidated line by line. All claims and liabilities within the group, transactions between group companies and unrealized profits and losses resulting from them have been eliminated.

Separate non-consolidated main statements of the consolidating entity (parent company) are published in the appendices to the interim consolidated financial statements. The parent company's basic reports have been prepared using the same accounting principles that have been applied in the preparation of the consolidated interim report, except for investments in subsidiaries and affiliates, which are reflected in the unconsolidated report using the acquisition cost method.

A company over which the parent company has control is considered a subsidiary company. A subsidiary is considered to be under the control of the parent company if the parent company directly or indirectly owns more than 50% of the subsidiary's voting shares or parts or is otherwise able to control the subsidiary's operational and financial policy.

Financial assets

The company has the following financial asset: cash. Financial assets are initially recognized at cost, this being the fair value of the consideration given. The acquisition cost includes all expenditures directly related to the purchase of the financial asset. All regular purchases and sales of financial assets in market value are recognized on the transaction date. Following initial recognition, financial assets are measured based on their type either at fair value, at acquisition cost or at amortized cost.

Financial assets are derecognized when the company loses the right to receive cash flows from the financial asset or it transfers the financial asset, the cash flows from the financial assets and the majority of risks and rewards to other parties.

Cash and cash equivalents

Cash and cash equivalents in the balance sheet and in the cash flow, statement include cash in bank accounts (except overdraft).

Foreign currency transactions and assets and liabilities denominated in a foreign currency

The company's functional currency is the Euro, all other currencies are deemed foreign currencies. Transactions denominated in foreign currencies are recorded on the basis of the foreign currency exchange rates of the European Central Bank officially valid on the transaction date.

Monetary assets and liabilities (receivables paid in cash and loans) denominated in foreign currency are translated at balance sheet date into Euros based on the official foreign exchange rates of the European Central Bank. Gains and losses on foreign currency revaluations are recognized in the income statement in the corresponding accounting period. Non-monetary assets and liabilities denominated in foreign currencies, which are not carried at fair value (eg. prepayments, property, plant and equipment and intangible assets), are not revalued at balance sheet date, but instead are recorded with the exchange rate of the European Central Bank that was valid on the transaction date.

Shares of subsidiaries and associates

A company over which the parent company has a dominant influence is considered a subsidiary company. Dominant influence is assumed if the parent company directly or through subsidiaries owns more than 50% of the subsidiary's voting rights. Dominant influence also exists if the parent company owns 50% or less of the voting power in the subsidiary, but the parent company: (1) has actual controlling influence over more than 50% of the voting power by agreement with other investors; (2) has a dominant influence over the company's financial and operating policy based on the articles of association or contract; (3) can appoint or recall the majority of the members of the executive management and higher management bodies (e.g. the company's management board and supervisory board); or (4) can determine the decisions of executive management and senior management meetings.

Investments in subsidiaries are recorded on the balance sheet using the acquisition cost method.

Receivables and prepayments

Accounts receivable are receivables arising from ordinary business transactions of the company. Accounts receivables are recorded using the amortized cost method (i.e. nominal value less impairment loss).

The collectability of the accounts receivable is considered separately by each customer. Accounts receivables, which partly or fully are not expected to be collected, are expensed and reported in the income statement as "Other operating expense". Receivables, collection of which is not feasible nor economically justified, are considered to be non-collectible and written-off from the balance sheet. Receipt of doubtful receivables previously written down is recognized as a decrease in the expense of doubtful receivables.

Inventories

Inventories are initially recognized at cost which comprises costs of purchase, production costs and other costs incurred in bringing the inventories to their present location and condition.

Inventories are expensed using the FIFO method.

Inventories are measured in the balance sheet at the lower of cost or net realizable value. Net realizable value is the estimated selling price of an annual report product in the ordinary course of business less the estimated costs of completion and those necessary to make the sale.

Plant, property and equipment and intangible assets

Property, plant and equipment are assets used in the company's own business activities with a useful life exceeding one year and the cost of at least 1 350 Euros.

A property, plant and equipment are initially recorded at cost which comprises the purchase price and other costs directly attributable to the acquisition that are necessary for bringing the asset to its operating condition and location. Property, plant and equipment are carried in the balance sheet at acquisition cost, less accumulated depreciation and any accumulated impairment losses.

If the major components of an item of property, plant and equipment have significantly different useful lives, these components shall be recognized initially as separate items of property, plant and equipment and separate depreciation rates shall be assigned to them depending on their useful lives.

An intangible asset is initially recorded at a cost which comprises the purchase price and other costs directly attributable to the acquisition. An intangible asset is carried in the balance sheet at its cost, less accumulated amortization and any accumulated impairment losses.

Pharmaceutical products in development are recorded as unfinished projects. Once products in development are approved for sale, the amounts will be allocated to product rights and will be amortized. Unfinished projects include also product acquisition costs representing product rights obtained from third parties possessing regulatory approvals in respective markets, however, production of which has not yet started. Product acquisition costs are reclassified as intangible assets in use and will be amortized once products are commercialized.

Minimal acquisition cost 1350

Useful life by assets group (years)

Assets group name	Useful life
Machinery and equipment	5-20
Other property, plant and equipment	2-5

Concessions, patents, licences, trademarks	10
---	----

The company performs an impairment test at each balance sheet date on those assets where there is any indication of potential impairment.

An impairment test is performed to determine the recoverable amount of an asset, which is the higher of the two indicators – fair value of an asset (less costs to sell) and its value in use. Value in use is the present value of estimated future cash flows expected to arise from the use of an asset and from the disposal at the end of its useful life.

When an impairment test is not feasible for an individual asset because the cash flows being generated by the asset are indistinguishable from the cash flows of the rest of the entity, an impairment test shall be performed for the cash-generating unit to which the asset belongs.

Assets are written down to their recoverable amount if the recoverable amount of the asset is lower than its carrying amount. The impairment loss is recognized on an accrual basis as an expense in the income statement under "Depreciation and impairment loss".

Products in development are subject to the annual impairment testing. These valuations reflect, among other things, the impact of changes to the development programs, the projected development and regulatory time frames and the current competitive environment.

Recording of property, plant and equipment and intangible assets is finished in case of disposal of the asset or in case the economic benefits are no longer expected from use or sale of the asset.

The straight-line method is used for depreciating property, plant and equipment. The depreciation rates are assigned to each item of property, plant and equipment or major component separately, based on the useful life of the specific item.

The straight-line method is used for amortizing intangible assets. The amortization rates are assigned to each item of intangible asset, based on the useful life of the specific item.

Leases

Lease transactions, where all material risks and rewards from the ownership of an asset are transferred to the lessee, are treated as finance lease. All other lease transactions are treated as operating leases.

Operating lease payments are recorded as expenses based on straight-line method over the entire lease period.

Financial liabilities

Financial liabilities (trade payables, received loans, accrued expenses) are initially measured at cost, which is the fair value of consideration received. The initial cost of financial liabilities includes all direct transaction costs. Subsequently the financial liabilities are recorded at amortized cost.

The amortized cost of short-term liabilities, in general, is equal to their nominal value. Therefore, they are recognized in the amount required to settle the liability. For calculating the amortized cost of long-term financial liabilities, the effective interest rate method is used.

A financial liability is derecognized when the obligation under the liability is discharged, cancelled or expires.

A financial liability is classified as long-term in the balance sheet if it is due more than 12 months after the balance sheet date. All other liabilities are classified as short-term.

Revenue recognition

Revenue from the sale of goods is recognized when all significant risks related to ownership of goods are transferred to the buyer, the sales revenue and transaction costs can be reliably measured and the receipt of payment from the transaction is probable. Revenue from services is recognized in the period the services are rendered, assuming that the receipt of payment from the transaction is probable and the sales revenue and the expenses related to providing the services can be reliably measured.

Taxation

According to the Income Tax Act, Estonian companies are not subject to pay income tax on the annual period profit. Income tax is paid on distribution of dividends, fringe benefits, gifts, donations, reception costs, expenses not related to business activities and transfer pricing adjustments. The tax rate is 20/80 of the taxable amount.

Related parties

The following are considered as related parties in the preparation of the interim report for J. Molner AS:

- owner;
- members of management board;
- companies under control or significant influence of aforementioned individuals or their close relatives.

Note 2 Cash and cash equivalents

(In Euros)

	30.06.2024	30.06.2023
Cash and cash equivalents	611 512	675 300
Total cash and cash equivalents	611 512	675 300

Note 3 Receivables and prepayments

(In Euros)

	30.06.2024	Allocation by remaining maturity	
		Within 12 months	1 - 5 years
Accounts receivable	309 551	309 551	0
Accounts receivable	309 551	309 551	0
Tax prepayments and receivables	33 106	33 106	0
Prepayments	185 539	175 944	9 595
Deferred expenses	173 389	173 389	0
Other paid prepayments	12 150	2 555	9 595
Total receivables and prepayments	528 196	518 601	9 595
	30.06.2023	Allocation by remaining maturity	
		Within 12 months	1 - 5 years
Accounts receivable	118 189	118 189	0
Accounts receivable	118 189	118 189	0
Tax prepayments and receivables	12 195	12 195	0
Prepayments	120 697	118 320	2 377
Deferred expenses	90 318	90 318	0
Other paid prepayments	30 379	28 002	2 377
Total receivables and prepayments	251 081	248 704	2 377

Note 4 Inventories

(In Euros)

	30.06.2024	30.06.2023
Raw materials	87 611	9 388
Raw materials	87 611	9 388
Total Inventories	87 611	9 388

Note 5 Shares of subsidiaries

(In Euros)

Shares of subsidiaries, general information					
Subsidiary's registry code	Name of subsidiary	Country of incorporation	Principal activity	Ownership interest (%)	
				31.12.2023	30.06.2024
16049586	The J. Molner Company OÜ	Estonia	Research and development in the field of biotechnology	100	100
87-2118750	The J. Molner Company LLC	United States of America	Wholesale	100	100

Acquired ownership interests			
Name of subsidiary	Acquired ownership interest %	Acquisition date	Cost of acquired ownership interest
The J. Molner Company OÜ	100	06.09.2022	1 600 000
The J. Molner Company LLC	100	09.01.2023	467

Note 6 Property, plant and equipment

(In Euros)

					Total
	Computers and computer systems	Other machinery and equipment	Machinery and equipment	Other property, plant and equipment	
30.06.2023					
Carried at cost	26 244	167 821	194 065	0	194 065
Accumulated depreciation	-1 734	-33 146	-34 880	0	-34 880
Residual cost	24 510	134 675	159 185	0	159 185
Acquisitions and additions	116	61 020	61 136	7 468	68 604
Other acquisitions and additions	116	61 020	61 136	7 468	68 604
Depreciation	-2 345	-11 793	-14 138	-249	-14 387
31.12.2023					
Carried at cost	26 360	228 841	255 201	7 468	262 669
Accumulated depreciation	-4 079	-44 939	-49 018	-249	-49 267
Residual cost	22 281	183 902	206 183	7 219	213 402
Acquisitions and additions	1 787	56 674	58 461	36 786	95 247
Other acquisitions and additions	1 787	56 674	58 461	36 786	95 247
Depreciation	-2 696	-13 212	-15 908	-1 230	-17 138
30.06.2024					
Carried at cost	28 147	285 515	313 662	44 254	357 916
Accumulated depreciation	-6 775	-58 151	-64 926	-1 479	-66 405
Residual cost	21 372	227 364	248 736	42 775	291 511

Note 7 Intangible assets

(In Euros)

				Total
	Computer software	Concessions, patents, licences, trademarks	Unfinished projects and prepayments	
30.06.2023				
Carried at cost	5 152	0	1 239 454	1 244 606
Accumulated depreciation	-1 030	0	0	-1 030
Residual cost	4 122	0	1 239 454	1 243 576
Acquisitions and additions	0	481 449	1 162 693	1 644 142
Depreciation	-258	-7 875	0	-8 391
31.12.2023				
Carried at cost	5 152	481 449	1 948 869	2 435 470
Accumulated depreciation	-1 288	-7 875	0	-9 163
Residual cost	3 864	473 574	1 948 869	2 426 307
Acquisitions and additions	0	27 847	358 589	386 436
Depreciation	-257	-25 233	0	-25 490
30.06.2024				
Carried at cost	5 152	509 296	2 307 458	2 821 906
Accumulated depreciation	-1 545	-33 108	0	-34 653
Residual cost	3 607	476 188	2 307 458	2 787 253

Note 8 Loan commitments

(In Euros)

	30.06.2024	Allocation by remaining maturity			Interest rate	Base currencies	Due date
		Within 12 months	1 - 5 years	Over 5 years			
Current loans							
Short-term shareholder loan, EUR	94 286	94 286			5%	EUR	31.12.2023
Short-term shareholder loan, USD	185 448	185 448			5%	USD	31.12.2023
Current loans total	279 734	279 734					
Non-current loans							
Long-term loan	20 954		20 954		5%	USD	20.09.2026
Long-term loan, USD	2 386 229		2 386 229		7%	USD	06.04.2028
Non-current loans total	2 407 183		2 407 183				
Loan commitments total	2 686 917	279 734	2 407 183				
	30.06.2023	Allocation by remaining maturity			Interest rate	Base currencies	Due date
		Within 12 months	1 - 5 years	Over 5 years			
Current loans							
Short-term shareholder loan, EUR	95 735	95 735			5%	EUR	31.12.2023
Short-term shareholder loan, USD	181 748	181 748			5%	USD	31.12.2023
Current loans total	277 483	277 483					
Non-current loans							
Long-term loan	829		829		5%	USD	20.09.2026
Long-term loan, USD	927 841		927 841		7%	USD	06.04.2028
Non-current loans total	928 670		928 670				
Loan commitments total	1 206 153	277 483	928 670				

Note 9 Payables and prepayments

(In Euros)

	30.06.2024	Within 12 months	Note
Trade payables	332 362	332 362	
Employee payables	105 990	105 990	10
Tax payables	88 552	88 552	
Other payables	219 178	219 178	
Other accrued expenses	219 178	219 178	
Prepayments received	27 226	27 226	
Deferred income	27 226	27 226	
Total payables and prepayments	773 308	773 308	
	30.06.2023	Within 12 months	Note
Trade payables	58 319	58 319	
Employee payables	78 537	78 537	10
Tax payables	72 756	72 756	
Other payables	0	0	
Other accrued expenses	0	0	
Prepayments received	13 895	13 895	
Deferred income	13 895	13 895	
Total payables and prepayments	223 510	223 510	

* In a US company, labor taxes are paid once a quarter, by the last day of the month following the end of the quarter.

Note 10 Employee payables

(In Euros)

	30.06.2024	30.06.2023
Remuneration liability	59 334	46 385
Vacation pay liability	46 656	32 153
Total employee payables	105 990	78 538

Note 11 Net sales

(In Euros)

	01.01.2024 - 30.06.2024	01.01.2023 - 30.06.2023
Net sales by geographical location		
Net sales in European Union		
Estonia	1 284	2 400
Latvia	38 171	19 320
Total net sales in European Union	39 455	21 720
Net sales outside of European Union		
United States of America	1 264 836	249 049
Canada	1 036	0
Total net sales outside of European Union	1 265 872	249 049
Total net sales	1 305 327	270 769
Net sales by operating activities		
Research and development in the field of biotechnology	1 176 178	270 769
Sale of Goods	129 149	0
Total net sales	1 305 327	270 769

Note 12 Miscellaneous operating expenses

(In Euros)

	01.01.2024 - 30.06.2024	01.01.2023 - 30.06.2023
Energy	14 180	2 031
Electricity	11 740	1 767
Heat energy	2 440	264
Water supply services	962	98
Miscellaneous office expenses	90 485	59 644
Travel expense	98 357	80 819
Training expense	19 515	59 636
State and local taxes	8 303	4 613
Other	306 420	113 309
Total miscellaneous operating expenses	538 222	320 150

Note 13 Labor expense

(In Euros)

	01.01.2024 - 30.06.2024	01.01.2023 - 30.06.2023
Wage and salary expense	550 963	369 011
Social security taxes	165 885	121 633
Option costs (reserve)	5 125	27 014
Total labor expense	721 973	517 658
Average number of employees in full time equivalent units	29	24
Average number of employees by types of employment:		
Person employed under employment contract	28	24
Person providing service under law of obligations, except for self-employed person	1	0

Note 14 Related parties

(In Euros)

Related party balances according to groups

SHORT TERM	30.06.2024	30.06.2023
Receivables and prepayments		
Management and higher supervisory body and individuals with material ownership interest and material influence of management and higher	0	27 641
Total receivables and prepayments	0	27 641

LOAN COMMITMENTS	31.12.2022	Loans received repayments	30.06.2023	Interest accrued for period
Management and higher supervisory body and individuals with material ownership interest and material influence of management and higher	274 178	16 830	277 483	6 497
Total loan commitments	274 178	16 830	277 483	6 497
LOAN COMMITMENTS	31.12.2023	Loans received repayments	30.06.2024	Interest accrued for period
Management and higher supervisory body and individuals with material ownership interest and material influence of management and higher	267 645	0	279 734	6 790
Total loan commitments	267 645	0	279 734	6 790

Remuneration and other significant benefits calculated for members of management and highest supervisory body		
	01.01.2024 - 30.06.2024	01.01.2023 - 30.06.2023
Remuneration	93 557	32 955

Note 15 non-consolidated statement of financial position

(In Euros)

	30.06.2024	31.12.2023	30.06.2023
Assets			
Current assets			
Cash and cash equivalents	0	3 457	25 788
Receivables and prepayments	7 948	0	5 429
Total current assets	7 948	3 457	31 217
Non-current assets			
Investments in subsidiaries and associates	1 600 467	1 600 467	1 600 000
Receivables and prepayments	1 929 388	2 410 447	1 434 647
Total non-current assets	3 529 855	4 010 914	3 034 647
Total assets	3 537 803	4 014 371	3 065 864
Liabilities and equity			
Liabilities			
Current liabilities			
Payables and prepayments	17 912	1 187	0
Total current liabilities	17 912	1 187	0
Non-current liabilities			
Loan liabilities	1 372 517	1 866 616	925 687
Total non-current liabilities	1 372 517	1 866 616	925 687
Total liabilities	1 390 429	1 867 803	925 687
Equity			
Issued capital	1 686 001	1 686 001	1 686 001
Share premium	612 327	612 327	612 327
Other reserves	26 836	21 711	27 014
Retained earnings (loss)	-173 471	-143 268	-143 268
Annual period profit (loss)	-4 319	-30 203	-41 897
Total equity	2 147 374	2 146 568	2 140 177
Total liabilities and equity	3 537 803	4 014 371	3 065 864

Note 16 non-consolidated income statement

(In Euros)

	01.01.2024 - 30.06.2024	01.01.2023 - 30.06.2023
Other operating expense	-12 233	-22 890
Employee expense	-5 125	-27 014
Total operating profit (loss)	-17 358	-49 904
Interest expenses	-44 081	0
Other financial income and expense	57 120	-5 385
Profit (loss) before tax	-4 319	13 392
Annual period profit (loss)	-4 319	-41 897

Note 17 non-consolidated statement of cash flows

(In Euros)

	01.01.2024 - 30.06.2024	01.01.2023 - 30.06.2023
Cash flows from operating activities		
Payments to suppliers for goods and services	-3 457	-117 645
Other cash flows from operating activities	0	-25
Total cash flows from operating activities	-3 457	-117 670
Cash flows from investing activities		
Loans given	0	-501 000
Interest received	0	48
Total cash flows from investing activities	0	-500 952
Total cash flows	-3 457	-618 622
Cash and cash equivalents at beginning of period	3 457	644 410
Change in cash and cash equivalents	-3 457	-618 622
Cash and cash equivalents at end of period	0	25 788

Note 18 non-consolidated statement of changes in equity


(In Euros)

					Total
	Issued capital	Share premium	Other reserves	Retained earnings (loss)	
30.06.2023	1 686 001	612 327	27 014	-185 165	2 140 177
Annual period profit (loss)	0	0	0	11 694	11 694
Changes in reserves	0	0	-5 303	0	-5 303
31.12.2023	1 686 001	612 327	21 711	-173 471	2 146 568
Governing and material influence ownership interest value of financial position	0	0	0	0	0
Governing and material influence on the value of holdings under the e equity method	0	0	0	0	0
Restated non- consolidated equity 31.12.2023	1 686 001	612 327	21 711	-173 471	2 146 568
Annual period profit (loss)	0	0	0	-4 319	-4 319
Changes in reserves	0	0	5 125	0	5 125
30.06.2024	1 686 001	612 327	26 836	-177 790	2 147 374

Signatures

The board has prepared the unaudited interim report of J. Molner AS for the first 6 months of the 2024 financial year and confirms the correctness of the data in the report.

The report completion date is: 16.09.2024.

A handwritten signature in blue ink, appearing to read 'Jason M. Grenfell-Gardner', with a large, stylized flourish above the name.

Jason Michael Atticus Grenfell-Gardner

Member of the Board